[The regulatory evaluation of tumor-agnostic drugs.]

Area of Science:

• Oncology
• Genomics
• Pharmacology

Background:

• Traditional oncology relies on anatomical and histological classifications.
• The mutational model in oncology offers a new paradigm for cancer treatment.
• Adapting health and regulatory systems is essential for this paradigm shift.

Purpose of the Study:

• To analyze the implications of transitioning from traditional to mutational models in oncology.
• To highlight the challenges agnostic oncology presents for drug development and regulatory pathways.

Main Methods:

• Literature review on oncology treatment models.
• Analysis of regulatory frameworks for drug authorization.
• Comparative study of traditional vs. mutational oncology approaches.

Main Results:

• The mutational model decouples cancer classification from strict anatomical and histological constraints.
• Agnostic oncology necessitates significant adaptations in clinical development and diagnostic-therapeutic strategies.
• Regulatory systems face challenges in evaluating and authorizing drugs based on molecular targets rather than tumor site.

Conclusions:

• The transition to agnostic oncology requires a comprehensive evolution of healthcare and regulatory systems.
• Adapting drug development, authorization, and evaluation processes is critical for embracing the mutational model.
• This paradigm shift promises more personalized and effective cancer treatments but demands systemic adaptation.